Global Myotonic Dystrophy Treatment Market

Myotonic Dystrophy Treatment Comprehensive Study by Type (Congenital-onset, Childhood- or juvenile-onset, Adult-onset, Mild), Treatment (Devices, Medications, Rehabilitative Therapy, Surgery), End-users (Hospitals, Specialty Clinics, Ambulatory Surgery Centers), Symptoms (Stiffness and Tightness of Muscles, Progressive Muscle Wasting, Muscle Weakness in Lower Legs, Neck, and Hands, Others) Players and Region - Global Market Outlook to 2027

Myotonic Dystrophy Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Myotonic Dystrophy Treatment?
Myotonic dystrophy is a sickness that influences the muscle mass and different physique systems. It is the most frequent shape of muscular dystrophy that starts offevolved in adulthood, normally in a person’s 20s or 30s. This ailment is characterised by means of innovative muscle loss and weakness. Myotonic dystrophy is brought on by using mutations (changes) in the DMPK gene or the CNBP (ZNF9) gene relying on the unique kind of myotonic dystrophy. The sickness is inherited in an autosomal dominant manner. Myotonic dystrophy may additionally be identified when a healthcare issuer observes signs and symptoms and signs and symptoms of the disease, and the prognosis may additionally be verified with checks of muscle characteristic and genetic testing. Treatment is primarily based on every person’s precise symptoms and signs and may also include bodily therapy, ache administration with medication, and session with specialists.

The market study is broken down by Type (Congenital-onset, Childhood- or juvenile-onset, Adult-onset and Mild) and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Myotonic Dystrophy Treatment market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Asklepios Kliniken GmbH (Germany), BioMarin Pharmaceutical, Inc., (United States), Eli Lilly (United States), Hoveround Corporation (United States), Mylan Pharmaceuticals Inc., (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States), Siemens Healthcare (Germany), Teva Pharmaceutical Industries Ltd., (Israel) and Wockhardt Ltd., (India) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Myotonic Dystrophy Treatment market by Type, Application and Region.

On the basis of geography, the market of Myotonic Dystrophy Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Devices will boost the Myotonic Dystrophy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Myotonic Dystrophy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Stiffness and Tightness of Muscles will boost the Myotonic Dystrophy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In 2020, Dr. Christian Höftberger, Board Member of RHÖN-KLINIKUM AG, commented on the new partnership with Asklepios: “The 22 new specialist nurses who have transferred from Asklepios to UKGM are only the beginning of our intensive cooperation in the areas of nursing and training. Together we shall strengthen the personnel situation at UKGM for the long-term, further improve patient care and reduce the work burden on our employees.”



Market Trend
  • Increase in R & D

Market Drivers
  • Rise in Prevalence of Chronic Diseases such as Cardiovascular, Neurovascular, and Arthritis

Opportunities
  • Increasing Healthcare Expenditure

Restraints
  • Currently no Cure or Specific Treatment for Myotonic Dystrophy

Challenges
  • Long-term Genetic disorder that affects Muscle Function


Key Target Audience
Regulatory bodies, Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Congenital-onset
  • Childhood- or juvenile-onset
  • Adult-onset
  • Mild
By Treatment
  • Devices
  • Medications
  • Rehabilitative Therapy
  • Surgery

By End-users
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers

By Symptoms
  • Stiffness and Tightness of Muscles
  • Progressive Muscle Wasting
  • Muscle Weakness in Lower Legs, Neck, and Hands
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Prevalence of Chronic Diseases such as Cardiovascular, Neurovascular, and Arthritis
    • 3.3. Market Challenges
      • 3.3.1. Long-term Genetic disorder that affects Muscle Function
    • 3.4. Market Trends
      • 3.4.1. Increase in R & D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Myotonic Dystrophy Treatment, by Type, Treatment, End-users, Symptoms and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Myotonic Dystrophy Treatment (Value)
      • 5.2.1. Global Myotonic Dystrophy Treatment by: Type (Value)
        • 5.2.1.1. Congenital-onset
        • 5.2.1.2. Childhood- or juvenile-onset
        • 5.2.1.3. Adult-onset
        • 5.2.1.4. Mild
      • 5.2.2. Global Myotonic Dystrophy Treatment by: Treatment (Value)
        • 5.2.2.1. Devices
        • 5.2.2.2. Medications
        • 5.2.2.3. Rehabilitative Therapy
        • 5.2.2.4. Surgery
      • 5.2.3. Global Myotonic Dystrophy Treatment by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
        • 5.2.3.3. Ambulatory Surgery Centers
      • 5.2.4. Global Myotonic Dystrophy Treatment by: Symptoms (Value)
        • 5.2.4.1. Stiffness and Tightness of Muscles
        • 5.2.4.2. Progressive Muscle Wasting
        • 5.2.4.3. Muscle Weakness in Lower Legs, Neck, and Hands
        • 5.2.4.4. Others
      • 5.2.5. Global Myotonic Dystrophy Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Myotonic Dystrophy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Asklepios Kliniken GmbH (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioMarin Pharmaceutical, Inc., (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hoveround Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan Pharmaceuticals Inc., (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Siemens Healthcare (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd., (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Wockhardt Ltd., (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Myotonic Dystrophy Treatment Sale, by Type, Treatment, End-users, Symptoms and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Myotonic Dystrophy Treatment (Value)
      • 7.2.1. Global Myotonic Dystrophy Treatment by: Type (Value)
        • 7.2.1.1. Congenital-onset
        • 7.2.1.2. Childhood- or juvenile-onset
        • 7.2.1.3. Adult-onset
        • 7.2.1.4. Mild
      • 7.2.2. Global Myotonic Dystrophy Treatment by: Treatment (Value)
        • 7.2.2.1. Devices
        • 7.2.2.2. Medications
        • 7.2.2.3. Rehabilitative Therapy
        • 7.2.2.4. Surgery
      • 7.2.3. Global Myotonic Dystrophy Treatment by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
        • 7.2.3.3. Ambulatory Surgery Centers
      • 7.2.4. Global Myotonic Dystrophy Treatment by: Symptoms (Value)
        • 7.2.4.1. Stiffness and Tightness of Muscles
        • 7.2.4.2. Progressive Muscle Wasting
        • 7.2.4.3. Muscle Weakness in Lower Legs, Neck, and Hands
        • 7.2.4.4. Others
      • 7.2.5. Global Myotonic Dystrophy Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Myotonic Dystrophy Treatment: by Type(USD Million)
  • Table 2. Myotonic Dystrophy Treatment Congenital-onset , by Region USD Million (2016-2021)
  • Table 3. Myotonic Dystrophy Treatment Childhood- or juvenile-onset , by Region USD Million (2016-2021)
  • Table 4. Myotonic Dystrophy Treatment Adult-onset , by Region USD Million (2016-2021)
  • Table 5. Myotonic Dystrophy Treatment Mild , by Region USD Million (2016-2021)
  • Table 6. Myotonic Dystrophy Treatment: by Treatment(USD Million)
  • Table 7. Myotonic Dystrophy Treatment Devices , by Region USD Million (2016-2021)
  • Table 8. Myotonic Dystrophy Treatment Medications , by Region USD Million (2016-2021)
  • Table 9. Myotonic Dystrophy Treatment Rehabilitative Therapy , by Region USD Million (2016-2021)
  • Table 10. Myotonic Dystrophy Treatment Surgery , by Region USD Million (2016-2021)
  • Table 11. Myotonic Dystrophy Treatment: by End-users(USD Million)
  • Table 12. Myotonic Dystrophy Treatment Hospitals , by Region USD Million (2016-2021)
  • Table 13. Myotonic Dystrophy Treatment Specialty Clinics , by Region USD Million (2016-2021)
  • Table 14. Myotonic Dystrophy Treatment Ambulatory Surgery Centers , by Region USD Million (2016-2021)
  • Table 15. Myotonic Dystrophy Treatment: by Symptoms(USD Million)
  • Table 16. Myotonic Dystrophy Treatment Stiffness and Tightness of Muscles , by Region USD Million (2016-2021)
  • Table 17. Myotonic Dystrophy Treatment Progressive Muscle Wasting , by Region USD Million (2016-2021)
  • Table 18. Myotonic Dystrophy Treatment Muscle Weakness in Lower Legs, Neck, and Hands , by Region USD Million (2016-2021)
  • Table 19. Myotonic Dystrophy Treatment Others , by Region USD Million (2016-2021)
  • Table 20. South America Myotonic Dystrophy Treatment, by Country USD Million (2016-2021)
  • Table 21. South America Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 22. South America Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 23. South America Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 24. South America Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 25. Brazil Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 26. Brazil Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 27. Brazil Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 28. Brazil Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 29. Argentina Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 30. Argentina Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 31. Argentina Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 32. Argentina Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 33. Rest of South America Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 35. Rest of South America Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 36. Rest of South America Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 37. Asia Pacific Myotonic Dystrophy Treatment, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 40. Asia Pacific Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 41. Asia Pacific Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 42. China Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 43. China Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 44. China Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 45. China Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 46. Japan Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 47. Japan Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 48. Japan Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 49. Japan Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 50. India Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 51. India Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 52. India Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 53. India Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 54. South Korea Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 55. South Korea Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 56. South Korea Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 57. South Korea Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 58. Australia Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 59. Australia Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 60. Australia Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 61. Australia Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 66. Europe Myotonic Dystrophy Treatment, by Country USD Million (2016-2021)
  • Table 67. Europe Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 68. Europe Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 69. Europe Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 70. Europe Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 71. Germany Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 72. Germany Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 73. Germany Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 74. Germany Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 75. France Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 76. France Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 77. France Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 78. France Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 79. Italy Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 80. Italy Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 81. Italy Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 82. Italy Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 83. United Kingdom Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 84. United Kingdom Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 85. United Kingdom Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 86. United Kingdom Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 87. Netherlands Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 88. Netherlands Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 89. Netherlands Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 90. Netherlands Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 91. Rest of Europe Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 92. Rest of Europe Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 93. Rest of Europe Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 94. Rest of Europe Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 95. MEA Myotonic Dystrophy Treatment, by Country USD Million (2016-2021)
  • Table 96. MEA Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 97. MEA Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 98. MEA Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 99. MEA Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 100. Middle East Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 101. Middle East Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 102. Middle East Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 103. Middle East Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 104. Africa Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 105. Africa Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 106. Africa Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 107. Africa Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 108. North America Myotonic Dystrophy Treatment, by Country USD Million (2016-2021)
  • Table 109. North America Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 110. North America Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 111. North America Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 112. North America Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 113. United States Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 114. United States Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 115. United States Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 116. United States Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 117. Canada Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 118. Canada Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 119. Canada Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 120. Canada Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 121. Mexico Myotonic Dystrophy Treatment, by Type USD Million (2016-2021)
  • Table 122. Mexico Myotonic Dystrophy Treatment, by Treatment USD Million (2016-2021)
  • Table 123. Mexico Myotonic Dystrophy Treatment, by End-users USD Million (2016-2021)
  • Table 124. Mexico Myotonic Dystrophy Treatment, by Symptoms USD Million (2016-2021)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Myotonic Dystrophy Treatment: by Type(USD Million)
  • Table 136. Myotonic Dystrophy Treatment Congenital-onset , by Region USD Million (2022-2027)
  • Table 137. Myotonic Dystrophy Treatment Childhood- or juvenile-onset , by Region USD Million (2022-2027)
  • Table 138. Myotonic Dystrophy Treatment Adult-onset , by Region USD Million (2022-2027)
  • Table 139. Myotonic Dystrophy Treatment Mild , by Region USD Million (2022-2027)
  • Table 140. Myotonic Dystrophy Treatment: by Treatment(USD Million)
  • Table 141. Myotonic Dystrophy Treatment Devices , by Region USD Million (2022-2027)
  • Table 142. Myotonic Dystrophy Treatment Medications , by Region USD Million (2022-2027)
  • Table 143. Myotonic Dystrophy Treatment Rehabilitative Therapy , by Region USD Million (2022-2027)
  • Table 144. Myotonic Dystrophy Treatment Surgery , by Region USD Million (2022-2027)
  • Table 145. Myotonic Dystrophy Treatment: by End-users(USD Million)
  • Table 146. Myotonic Dystrophy Treatment Hospitals , by Region USD Million (2022-2027)
  • Table 147. Myotonic Dystrophy Treatment Specialty Clinics , by Region USD Million (2022-2027)
  • Table 148. Myotonic Dystrophy Treatment Ambulatory Surgery Centers , by Region USD Million (2022-2027)
  • Table 149. Myotonic Dystrophy Treatment: by Symptoms(USD Million)
  • Table 150. Myotonic Dystrophy Treatment Stiffness and Tightness of Muscles , by Region USD Million (2022-2027)
  • Table 151. Myotonic Dystrophy Treatment Progressive Muscle Wasting , by Region USD Million (2022-2027)
  • Table 152. Myotonic Dystrophy Treatment Muscle Weakness in Lower Legs, Neck, and Hands , by Region USD Million (2022-2027)
  • Table 153. Myotonic Dystrophy Treatment Others , by Region USD Million (2022-2027)
  • Table 154. South America Myotonic Dystrophy Treatment, by Country USD Million (2022-2027)
  • Table 155. South America Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 156. South America Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 157. South America Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 158. South America Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 159. Brazil Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 160. Brazil Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 161. Brazil Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 162. Brazil Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 163. Argentina Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 164. Argentina Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 165. Argentina Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 166. Argentina Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 167. Rest of South America Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 168. Rest of South America Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 169. Rest of South America Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 170. Rest of South America Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 171. Asia Pacific Myotonic Dystrophy Treatment, by Country USD Million (2022-2027)
  • Table 172. Asia Pacific Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 173. Asia Pacific Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 174. Asia Pacific Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 175. Asia Pacific Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 176. China Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 177. China Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 178. China Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 179. China Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 180. Japan Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 181. Japan Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 182. Japan Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 183. Japan Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 184. India Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 185. India Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 186. India Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 187. India Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 188. South Korea Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 189. South Korea Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 190. South Korea Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 191. South Korea Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 192. Australia Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 193. Australia Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 194. Australia Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 195. Australia Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 196. Rest of Asia-Pacific Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 198. Rest of Asia-Pacific Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 200. Europe Myotonic Dystrophy Treatment, by Country USD Million (2022-2027)
  • Table 201. Europe Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 202. Europe Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 203. Europe Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 204. Europe Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 205. Germany Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 206. Germany Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 207. Germany Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 208. Germany Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 209. France Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 210. France Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 211. France Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 212. France Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 213. Italy Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 214. Italy Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 215. Italy Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 216. Italy Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 217. United Kingdom Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 218. United Kingdom Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 219. United Kingdom Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 220. United Kingdom Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 221. Netherlands Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 222. Netherlands Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 223. Netherlands Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 224. Netherlands Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 225. Rest of Europe Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 226. Rest of Europe Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 227. Rest of Europe Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 228. Rest of Europe Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 229. MEA Myotonic Dystrophy Treatment, by Country USD Million (2022-2027)
  • Table 230. MEA Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 231. MEA Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 232. MEA Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 233. MEA Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 234. Middle East Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 235. Middle East Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 236. Middle East Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 237. Middle East Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 238. Africa Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 239. Africa Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 240. Africa Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 241. Africa Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 242. North America Myotonic Dystrophy Treatment, by Country USD Million (2022-2027)
  • Table 243. North America Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 244. North America Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 245. North America Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 246. North America Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 247. United States Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 248. United States Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 249. United States Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 250. United States Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 251. Canada Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 252. Canada Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 253. Canada Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 254. Canada Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 255. Mexico Myotonic Dystrophy Treatment, by Type USD Million (2022-2027)
  • Table 256. Mexico Myotonic Dystrophy Treatment, by Treatment USD Million (2022-2027)
  • Table 257. Mexico Myotonic Dystrophy Treatment, by End-users USD Million (2022-2027)
  • Table 258. Mexico Myotonic Dystrophy Treatment, by Symptoms USD Million (2022-2027)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Myotonic Dystrophy Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Myotonic Dystrophy Treatment: by Treatment USD Million (2016-2021)
  • Figure 6. Global Myotonic Dystrophy Treatment: by End-users USD Million (2016-2021)
  • Figure 7. Global Myotonic Dystrophy Treatment: by Symptoms USD Million (2016-2021)
  • Figure 8. South America Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 9. Asia Pacific Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 10. Europe Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 11. MEA Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 12. North America Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 13. Global Myotonic Dystrophy Treatment share by Players 2021 (%)
  • Figure 14. Global Myotonic Dystrophy Treatment share by Players (Top 3) 2021(%)
  • Figure 15. Global Myotonic Dystrophy Treatment share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Asklepios Kliniken GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Asklepios Kliniken GmbH (Germany) Revenue: by Geography 2021
  • Figure 19. BioMarin Pharmaceutical, Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 20. BioMarin Pharmaceutical, Inc., (United States) Revenue: by Geography 2021
  • Figure 21. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lilly (United States) Revenue: by Geography 2021
  • Figure 23. Hoveround Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. Hoveround Corporation (United States) Revenue: by Geography 2021
  • Figure 25. Mylan Pharmaceuticals Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 26. Mylan Pharmaceuticals Inc., (United States) Revenue: by Geography 2021
  • Figure 27. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 29. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer, Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Siemens Healthcare (Germany) Revenue: by Geography 2021
  • Figure 33. Teva Pharmaceutical Industries Ltd., (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries Ltd., (Israel) Revenue: by Geography 2021
  • Figure 35. Wockhardt Ltd., (India) Revenue, Net Income and Gross profit
  • Figure 36. Wockhardt Ltd., (India) Revenue: by Geography 2021
  • Figure 37. Global Myotonic Dystrophy Treatment: by Type USD Million (2022-2027)
  • Figure 38. Global Myotonic Dystrophy Treatment: by Treatment USD Million (2022-2027)
  • Figure 39. Global Myotonic Dystrophy Treatment: by End-users USD Million (2022-2027)
  • Figure 40. Global Myotonic Dystrophy Treatment: by Symptoms USD Million (2022-2027)
  • Figure 41. South America Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 42. Asia Pacific Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 43. Europe Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 44. MEA Myotonic Dystrophy Treatment Share (%), by Country
  • Figure 45. North America Myotonic Dystrophy Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Asklepios Kliniken GmbH (Germany)
  • BioMarin Pharmaceutical, Inc., (United States)
  • Eli Lilly (United States)
  • Hoveround Corporation (United States)
  • Mylan Pharmaceuticals Inc., (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
  • Siemens Healthcare (Germany)
  • Teva Pharmaceutical Industries Ltd., (Israel)
  • Wockhardt Ltd., (India)
Select User Access Type

Key Highlights of Report


Feb 2022 237 Pages 53 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Myotonic Dystrophy Treatment Market Quantitative research analysis
Global Myotonic Dystrophy Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Asklepios Kliniken GmbH (Germany), BioMarin Pharmaceutical, Inc., (United States), Eli Lilly (United States), Hoveround Corporation (United States), Mylan Pharmaceuticals Inc., (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States), Siemens Healthcare (Germany), Teva Pharmaceutical Industries Ltd., (Israel) and Wockhardt Ltd., (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Myotonic Dystrophy Treatment Market to reach USD Million by 2027.

Know More About Global Myotonic Dystrophy Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Telehealth Technology Comprehensive Study by Application (Teleradiology, Telepsychiatry, Telepathology, Teledermatology, Telecardiology, Others), End-user (Healthcare Providers, Payers, Patients, Ot...
$ 4000
Graft Preparation System Comprehensive Study by End Users (Hospitals, Ambulatory Surgery Centers, Others), Graft Type (Skin, Ligament / Tendon, Bone) Players and Region - Global Market Outlook to 203...
$ 3400
Post Operative Pain Management Comprehensive Study by Route of Administration (Injectable Postoperative Pain Management, Oral Postoperative Pain Management, Transdermal Postoperative Pain Management,...
$ 3500
Virtual Fitness App Comprehensive Study by Type (Pay by course, Pay by time, Free course), Application (Millennials, Gen Z, Gen X, Baby Boomers), Training (Yoga, HIIT, Pilates, Barre, Others), Device...
$ 3800
Optical Lens Shape Tracers Comprehensive Study by Application (Eyeglass Lens, Microscope Lens, Camera Lens, Others), Product Type (Automatic, Manual), End-user (Hospitals, Clinics, Eye-care center, O...
$ 3800
Retinal Disorders Therapy- Comprehensive Study by Disease Generation (Macular Degeneration, Dry Macular Degeneration, Wet Macular Degeneration, Diabetic Retinopathy, Others), Distribution Channel (H...
$ 3800